

Date: 31st July 2025
Ref: CORP 25.26 - 086

Dear xxx

Freedom of Information request: Urothelial Cancer (CORP 25/26 – 086)

Thank you for your request for information which the Trust received on 15th July 2025.

Your Request:

- 1) *How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:*
 - *Atezolizumab (Tecentriq)*
 - *Avelumab (Bavencio)*
 - *Carboplatin single agent or in any other combination*
 - *Carboplatin with Gemcitabine*
 - *Carboplatin with Gemcitabine + Avelumab (Bavencio)*
 - *Carboplatin with Paclitaxel*
 - *Cisplatin single agent or in any other combination*
 - *Cisplatin with Gemcitabine*
 - *Cisplatin with Gemcitabine + Nivolumab (Opdivo)*
 - *Cisplatin with Gemcitabine + Avelumab (Bavencio)*
 - *Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)*
 - *Nivolumab (Opdivo)*
 - *Pembrolizumab (Keytruda)*
 - *Other active systemic anti-cancer therapy*
 - *Palliative care only*
 - *Erdafitinib*
- 2) *How many patients have been treated for metastatic Urothelial cancer in the past 3 months with the following systemic anti-cancer therapies:*
 - *Carboplatin single agent or in any other combination*
 - *Carboplatin with Gemcitabine*
 - *Carboplatin with Gemcitabine + Avelumab (Bavencio)*
 - *Carboplatin with Paclitaxel*
 - *Cisplatin single agent or in any other combination*
 - *Cisplatin with Gemcitabine*
 - *Cisplatin with Gemcitabine + Avelumab (Bavencio)*
- 3) *Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?*

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.

Please find the Trust's response below:

1) How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

- **Atezolizumab (Tecentriq) - <6***
- **Avelumab (Bavencio) - <6***
- **Carboplatin single agent or in any other combination - 0**
- **Carboplatin with Gemcitabine - 8**
- **Carboplatin with Gemcitabine + Avelumab (Bavencio) - 0**
- **Carboplatin with Paclitaxel - 0**
- **Cisplatin single agent or in any other combination - 0**
- **Cisplatin with Gemcitabine - 7**
- **Cisplatin with Gemcitabine + Nivolumab (Opdivo) - 0**
- **Cisplatin with Gemcitabine + Avelumab (Bavencio) - 0**
- **Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda) - 0**
- **Nivolumab (Opdivo) - 0**
- **Pembrolizumab (Keytruda) - 0**
- **Other active systemic anti-cancer therapy - <6***
- **Palliative care only - 9**
- **Erdafitinib – 0**


* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

2) How many patients have been treated for metastatic Urothelial cancer in the past 3 months with the following systemic anti-cancer therapies:

- **Carboplatin single agent or in any other combination - 0**
- **Carboplatin with Gemcitabine - <6***
- **Carboplatin with Gemcitabine + Avelumab (Bavencio) - 0**
- **Carboplatin with Paclitaxel - 0**
- **Cisplatin single agent or in any other combination - 0**
- **Cisplatin with Gemcitabine - <6***
- **Cisplatin with Gemcitabine + Avelumab (Bavencio) – 0**

* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



3) Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Velindre University NHS Trust is currently participating in the following clinical trials for the treatment of urothelial cancer:

1. IO102-IO103-022

Full title: A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head and Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)

Number of participants recruited: 8

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.


You should forward your complaint to:

Mr Ian Bevan via FOI.VUNHST@wales.nhs.uk
Head of Information Governance
Velindre University NHS Trust
2, Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales
2nd Floor
Churchill House,
Churchill Way
Cardiff
CF10 2HH
Telephone: 0330 414 6421
email: wales@ico.org.uk

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



Yours sincerely

**Non Gwilym
Interim Director of Corporate Governance**

Velindre University NHS Trust
2 Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.

